Back to feed

Big Pharma Can Rival Big Software

a16z News

Nov 13, 2026

11/13/2026

Improving The Odds Of A Commercially Differentiated Drug And Reducing Time To Approval Can Create Significant Value In Pharma

Big Pharma Can Rival Big Software · a16z News

Business, Finance & Industries · Nov 13, 2026

Pharma’s concentrated, patent-protected revenue model means a single successful drug can generate software-scale returns over many years, making AI valuable if it improves the odds and speed of developing commercially differentiated medicines.


11/13/2026

AI-Enabled Drug Discovery Could Reframe Pharma Valuation By Valuing The Discovery Engine And Enabling More Predictable Diversified Pipelines

Big Pharma Can Rival Big Software · a16z News

Business, Finance & Industries · Nov 13, 2026

If AI makes drug discovery reliably repeatable, investors may begin valuing pharmaceutical discovery platforms and infrastructure—not just approved drugs and late-stage assets—potentially enabling more predictable growth, diversified pipelines, and less dependence on blockbuster franchises threatened by patent expirations.


11/13/2026

Bio X AI Market Shows Commercial Adoption Of Model Platforms While Full-Stack Drug Development Remains Contingent On Clinical Validation

Big Pharma Can Rival Big Software · a16z News

Science, Technology & Innovation · Nov 13, 2026

The Bio × AI market is developing around both pharma-enabling platforms and vertically integrated drug developers, with commercial partnerships signaling growing confidence in molecular-design tools while scarce biological data and the need for wet-lab and clinical validation keep clinical translation as the ultimate test.


11/13/2026

AI Could Reduce Risk-Adjusted Drug Development Costs By Increasing Clinical Success Rates And Shortening Time to Approval Across the Pipeline

Big Pharma Can Rival Big Software · a16z News

Business, Finance & Industries · Nov 13, 2026

AI could materially reduce drug-development costs by increasing clinical success rates and shortening approval timelines across target selection, candidate screening, trial execution, and regulatory work. Given that fewer than 5% of candidates succeed, development averages 13 years, and successful drugs cost nearly $2 billion including failures, AI may make more therapies economically viable, increase the number of development attempts, and expand—not replace—wet-lab experimentation, benefiting CROs, lab automation, and specialized data providers.